Calcified Tissue International

, Volume 49, Supplement 1, pp S64–S67 | Cite as

Fluoride therapy for osteoporosis: A review of dose response, duration of treatment, and skeletal sites of action

  • B. A. Dure-Smith
  • M. E. Kraenzlin
  • S. M. Farley
  • C. R. Libanati
  • E. E. Schulz
  • D. J. Baylink
Factors Affecting Bone Metabolism and Osteoporosis


Osteoporosis is a disease characterized by a reduction in bone density which predisposes to fracture after even minimal trauma. Fluoride, because it has consistently been shown to stimulate bone formation and increase trabecular bone density, has been widely studied for the treatment of osteoporosis. The article focuses on the dose response, duration of treatment, and skeletal sites of action of fluoride; we also include comments on the effect of fluoride on vertebral and appendicular fracture rates. The skeletal response to fluoride doses, ranging from 15 to 43 mg elemental fluoride per day, included a linear increase in spinal bone density at an average rate of 1.25±0.91 mg/cm3 per month. The rate of increase in spinal bone density was related to the dose of fluoride (r=0.34,P<0.03). Spinal bone density had increased above the fracture threshold in 44% of patients treated with fluoride for 32±10 months. The time required to achieve this goal was, however, influenced by the pretreatment spinal bone density and interpatient variation in response to fluoride treatment. Patients whose spinal bone density remained below the fracture threshold had lower pretreatment bone densities and/or slower rates of increase in spinal bone density (P<0.001). The osteogenic effect of fluoride was not limited to the spine. After 2 years of fluoride therapy, we found bone density in the femoral condyle (measured by QCT) to have increased by 13±2.6 mg/cm3 (n=38,P<0.001); bone density in the hip (measured by DPA) was increased by 0.0261±0.015 g/cm2 (n=55,P<0.025). The efficacy of fluoride therapy to reduce fractures is not well established. Recently, investigators from the Mayo Clinic and Henry Ford Hospital reported fluoride had no effect on the vertebral fracture rate despite a significant increase in spinal bone density, but this finding has not been supported by findings in other studies. Moreover, our preliminary analysis of over 500 fluoride-treated patients found a time-dependent decrease in vertebral fracture rate related to a corresponding increase in spinal bone density. We conclude that these data, together with the many other positive international findings related to fluoride, justify continued investigation of this potent agent for the treatment of osteoporosis.

Key words

Osteoporosis Fluorides 


  1. 1.
    Farley JR, Wergedal JE, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 222:330–332PubMedCrossRefGoogle Scholar
  2. 2.
    Van Kesteren RG, Duursma SA, Visser WJ, van der Sluys V, Backer Dirks O (1982) Fluoride in serum and bone during treatment of osteoporosis with sodium fluoride, calcium, and vitamin D. Metab Bone Dis Rel Res 4:31CrossRefGoogle Scholar
  3. 3.
    Farley SM, Wergedal JE, Smith L, Lyndy MW, Farley JR, Baylink DJ (1987) Fluoride therapy for osteoporosis: characterisation of the skeletal response by serial measurements of serum alkaline phosphatase activity. Metabolism 36:211–218PubMedCrossRefGoogle Scholar
  4. 4.
    Farley SMG, Perkel V, Tudtud-Hans LA, Mariano-Menez MR, Libanati CR, Schulz EE, Baylink DJ (1990) Fluoride and calcium therapy for osteoporosis increases trabecular vertebral bone density above the fracture threshold. In: DeLuca HF, Mazess R (eds) Osteoporosis: physiological basis, assessment and treatment. Elsevier, New York, pp 187–192Google Scholar
  5. 5.
    Riggs BL, Hodgson SF, Hoffman DL, Kelly PJ, Johnson KA, Taves D (1980) Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence. JAMA 243:446–449PubMedCrossRefGoogle Scholar
  6. 6.
    Briancon D, Meunier PJ (1981) Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin North Am 12:629–648PubMedGoogle Scholar
  7. 7.
    Duursma JH, Glerum A, Van Dijak A, Bosch R, Kerkhoff H, Van Paten J, Raymakers JA (1987) Responders and nonre-sponders after fluoride therapy in osteoporosis. Bone 8:131–136PubMedCrossRefGoogle Scholar
  8. 8.
    Budden FH, Bayley TA, Harrison JE, Jose RG, Muray TM, Sturtridge WC, Kandel R, Vieth R, Strauss AL, Goodwin S (1988) The effects of fluoride on bone histology in postmenopausal osteoporosis. J Bone Miner Res 3:127–132PubMedGoogle Scholar
  9. 9.
    Kraenzlin ME, Kraenzlin C, Farley SMG, Fitzsimmons RJ, Baylink DJ (1990) Fluoride pharmacokinetics in good and poor responders to fluoride therapy. J Bone Miner Res 5 (Suppl 1): 49–52Google Scholar
  10. 10.
    Odvina CV, Wergedal JE, Libanati CR, Schultz EE, Baylink DJ (1988) Relationship between trabecular vertebral body density and fractures: a quantitative definition of osteoporosis. Metabolism 37:221–228PubMedCrossRefGoogle Scholar
  11. 11.
    Bell GH, Dunbar O, Beck JS, Gibb A (1967) Variations in strength of vertebrae with age and their relation to osteoporosis. Calcif Tissue Res 1:75–86PubMedCrossRefGoogle Scholar
  12. 12.
    Nokso-Koivisto VM, Alhava EM, Olkkonen H (1976) Measurement of cancellous bone strength, correlations with mineral density: aging and disease. Ann Clin Res 8:399–402PubMedGoogle Scholar
  13. 13.
    Farley SM, Libanati CR, Odvina CV, Smith L, Iliel L, Wakley GK, Kilcoyne R, Schulz EE, Baylink DJ (1989) The efficacy of long-term fluoride and calcium therapy acting to correct the deficit of spinal bone density in osteoporosis. J Clin Epidemiol. 42:1067–1074PubMedCrossRefGoogle Scholar
  14. 14.
    Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS (1983) Relationships between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis J Clin Invest 72:1396–1409PubMedCrossRefGoogle Scholar
  15. 15.
    Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM (1985) The role of three-dimensional trabecular microconstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594–597PubMedGoogle Scholar
  16. 16.
    Aaron JE, Makins NB, Sagreiya K (1987) The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 215:260–271PubMedGoogle Scholar
  17. 17.
    Baylink DJ, Duane PB, Farley JR (1983) Monofluorophosphate physiology: the effects of fluoride on bone. Caries Res 17 (Suppl 1): 56–76PubMedCrossRefGoogle Scholar
  18. 18.
    Taves DR (1970) New approach to the treatment of bone disease with fluoride. Fed Proc 29:1185–1187PubMedGoogle Scholar
  19. 19.
    Dambacher MA, Lauffenurger T, Lammle B, Haas HC (1978) Long-term effects of sodium fluoride in osteoporosis. In: Courvoisier, B, Donath A, Baud C (eds) Fluoride and bone. Hans Huber Bern, pp 238–241Google Scholar
  20. 20.
    Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM (1982) Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 306:446–450PubMedCrossRefGoogle Scholar
  21. 21.
    Farley SM, Libanati CR, Mariano-Menez MR, Tudtud-Hans LA, Sxhulz EE, Baylink DJ (1990) Fluoride therapy for osteoporosis promotes a progressive increase in spinal bone density. J Bone Miner Res 5 (Suppl 1):37–42Google Scholar
  22. 22.
    Jowsey J, Riggs BL, Kelly PJ, Hoffman DL (1972) Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med 53:43–49PubMedCrossRefGoogle Scholar
  23. 23.
    Schulz E, Libanati CR, Farley SM, Kirk G, Baylink DJ (1984) Early scintigraphic changes in fluoride treated osteoporotics and comparison with other methods. In: Christiansen C, Arnaud CD, Nordia BEC, Parfitt AM, Peck WA, Riggs BL (eds) Osteoporosis, vol 2. International Symposium on Osteoporosis, Copenhagen, pp 701–703Google Scholar
  24. 24.
    Farley JR, Wergedal JE, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 222:330–332PubMedCrossRefGoogle Scholar
  25. 25.
    Ringe JD, Kruse HP, Kuhlencordt F (1977) Long-term treatment of primary osteoporosis by sodium fluoride. In: Courvoisier B, Donath A (eds) Fluoride and bone. Hans Huber, Bern, pp 228–231Google Scholar
  26. 26.
    Manzke E, Chestnut CH, Wergedal JE, Baylink DJ, Nelp WB (1975) Relationship between local and total bone mass in osteoporosis. Metabolism 24:605–615PubMedCrossRefGoogle Scholar
  27. 27.
    Schulz EE, Libanati CR, Farley SM, Kirk GA, Baylink DJ (1984) Skeletal scintigraphic changes in osteoporosis treated with sodium fluoride: concise communication. J Nucl Med 25:651–655PubMedGoogle Scholar
  28. 28.
    Kraenzlin ME, Schulz EE, Libanati CR, Tudtud-Hans LA, Mariano-Menez MR, Baylink DJ (1989) Medical management of osteoporosis of the hip. In: Kleerekoper M, Krane SM (eds) Clinical disorders of bone and mineral metabolism. Mary Ann Liebert Publications, New York, pp 293–301Google Scholar
  29. 29.
    Riggs BL, Hodgson SF, O'Fallon MW, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton JL (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809PubMedCrossRefGoogle Scholar
  30. 30.
    Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, Prost A, Zeigler G, Netter P (1988) Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet ii:361–365CrossRefGoogle Scholar
  31. 31.
    Pak CYC, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Hohnson K (1989) Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 68:150–159PubMedCrossRefGoogle Scholar
  32. 32.
    Heaney RP, Baylink DJ, Johnston CC Jr, Melton III LJ, Meunier PJ, Murray TM, Nagant de Deuxchaisnes C (1989) Fluoride therapy for the vertebral crush fracture syndrome: a status report. Ann Intern Med 111:678–680PubMedGoogle Scholar
  33. 33.
    Farley SM, Wergedal JE, Farley JR, Javier GN, Schulz EE, Libanati CR, Talbot JR, Mohan SS, Perkel VS, Baylink DJ (1990) Fluoride decreases spinal fracture rate: a study of over 500 patients. ASBMR In: Overgaard K, Christiansen C (eds) Thrid International Symposium on Osteoporosis. Handelstrykkeriet Aalborg ApS. Aalborg, Denmark, p. 141:516Google Scholar
  34. 34.
    Gutteridge DH, Price RI, Nicholson GC, Kent GN, Retllack RW, Devlin RD, Worth GK, Glancy JJ, Michell P, Gruber H (1984) Fluoride in osteoporotic vertebral fractures—trabecular increase, vertebral protection, femoral fractures. In: Christiansen C, Arnaud, CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL (eds) Osteoporosis, vol 2. International Symposium on Osteoporosis, Copenhagen, pp 705–707Google Scholar
  35. 35.
    Hedlund LR, Gallagher JC (1989) Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res 4:223–225PubMedGoogle Scholar
  36. 36.
    Riggs BL, Baylink DJ, Kleerekoper M, Lane JM, Melton LJ, Meunier PJ (1987) Incidence of hip fractures in osteoporotic women treated with sodium fluoride. J Bone Miner Res 2:123–126PubMedCrossRefGoogle Scholar
  37. 37.
    Simonen O, Laitinen O (1985) Does fluoridation of drinking water prevent bone fragility and osteoporosis. Lancet ii:432–434CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1991

Authors and Affiliations

  • B. A. Dure-Smith
    • 1
  • M. E. Kraenzlin
    • 1
  • S. M. Farley
    • 1
  • C. R. Libanati
    • 1
  • E. E. Schulz
    • 1
  • D. J. Baylink
    • 1
  1. 1.Department of MedicineLoma Linda University and Jerry L. Pettis Memorial Veterans Administration HospitalLoma LindaUSA

Personalised recommendations